Understand the source comparison
Cibinetide: Neuroprotective Peptide Comparison
Cibinetide's position in the neuroprotective peptide landscape becomes clearer when receptor mechanism, injury model efficacy, and hematopoietic risk are compared side by side. Cibinetide (ARA 290) Beta-common receptor (βcR/TPR complex) Stroke (MCAO), TBI, spi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cibinetide's position in the neuroprotective peptide landscape becomes clearer when receptor mechanism, injury model efficacy, and hematopoietic risk are compared side by side.
- Cibinetide (ARA 290)
- Beta-common receptor (βcR/TPR complex)
- Stroke (MCAO), TBI, spinal cord injury, myocardial infarction, renal ischemia-reperfusion
- None at therapeutic doses (up to 300 µg/kg in rodents)
- 4–6 hours (rodent SC)
- Tissue protection without erythropoiesis. Ideal for acute injury models where EPO's thrombotic risk is unacceptable
- Full-length EPO
- Erythropoietin receptor (EPOR homodimer)
- Stroke, TBI, myocardial infarction (early preclinical data)
- Strong. Dose-dependent increase in hematocrit and reticulocyte count
- 8–12 hours (rodent IV); 24 hours (human IV)
- Potent neuroprotection but carries thrombotic risk from elevated hematocrit. Unsuitable for non-anemic populations
- Carbamylated EPO (CEPO)
- Beta-common receptor (partial binding)
- Stroke (mixed results), some TBI models
- Minimal to none
- Variable (heterogeneous mixture)
- Eliminates erythropoiesis but inconsistent batch-to-batch activity limits reproducibility
- Cerebrolysin
- Multiple (neurotrophic peptide mixture)
- Stroke, TBI, Alzheimer's disease, vascular dementia
- None
- Not well-characterized (peptide mixture)
- Broader efficacy across acute and chronic models but undefined mechanism complicates dosing optimization
- Dihexa
- Hepatocyte growth factor receptor (c-Met)
- Cognitive impairment models, some TBI models
- 2–3 hours (rodent oral)
- Promotes synaptogenesis and cognitive enhancement. Less effective for acute apoptotic injury